U.S. Genomics Inc. is now called Pathogenetix Inc., according to Securities & Exchange Commission filings detailing the company’s latest private funding round.
The Woburn, Mass.-based biotech raised $2.2 million from an offering of equity and debt.
While the $1.3 million equity sale is closed, the company still hopes to add $300,000 more to the $900,000 the company raised from a debt offering.
U.S. Genomics developed single-molecule diagnostic technology for pathogen detection and has raised $61 million in venture-based and private funding since its 1997 launch, according to its website. In 2008, the company raised $4.5 million in equity-based financing from Becton, Dickinson & Co. (NYSE:BDX) as it entered into a development partnership with the company, according to Xconomy.
U.S. Genomics lists Healthcare Ventures investor Augustine Lawlor and CB Health Ventures partner Enrico Petrillo as board members and both are named as related persons in the new Pathogenetix filings. Their firms are also listed as previous investors on U.S. Genomics’ website.
Excel Venture Management managing director Stephen Gullans is also listed as a board member on the filings, but his firm is not an investor in U.S. Genomics, according to its website.
